Koru Medical Systems Withdraws 510(K) Application For FreedomEDGE With Phesgo In U.S. To Focus On Alternative Higher Volume Molecules
"Looking ahead for the remainder of 2026, we expect our international core growth to moderate as we navigate regional launch dynamics in specific European markets converting to pre-filled syringes. We remain
Koru Medical stopped trying to get approval in the U.S. for one product, so they can focus on other medicines that might sell more. When a company changes plans like this, watch whether their new focus actually helps them grow.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.